beta thalassemia

Vertex Launches Casgevy: Revolutionary Gene Editing for Genetic Diseases

📚 Vertex Pharmaceuticals launches Casgevy, targeting gene editing therapies for sickle cell disease and beta thalassemia. 💰 This move strengthens Vertex's position in genetic diseases and aims for significant impact in the field.